Wells Fargo Raises Abbott Laboratories (ABT) Price Target to $120

Wells Fargo maintained its Overweight rating on Abbott Laboratories (NYSE: ABT) on October 23, 2026, while raising its price target from $119.00 to $120.00. The research note from Wells Fargo reflects the firm's forward-looking perspective on the health care company following its latest operational updates. Abbott Laboratories closed at $102.86 on the day of the rating adjustment.

ABT Abbott Laboratories

$102.51 ▼ -15.41% year to date

1M 3M YTD

Daily close · Oct 22, 2026

Wells Fargo's Call on Abbott Laboratories

In its research note published on October 23, 2026, Wells Fargo kept an Overweight rating on Abbott Laboratories and moved its target up to $120.00 from its prior target of $119.00. This follows an earlier note from the firm on October 22, 2026, which had set the target at $119.00. Other Wall Street firms have also adjusted their views recently, with Citigroup maintaining a Buy rating and lowering its target to $122.00 on October 22, 2026, and RBC Capital keeping an Outperform rating while reducing its target to $125.00 on the same day.

Other Institutional Activity in Abbott Laboratories

Capital International Investors trimmed its position in Abbott Laboratories by 2,842,222 shares during the period ended June 30, 2026, marking a 7.6% decrease. The fund ended the quarter with 34,654,113 shares valued at approximately $3.56 billion.

Abbott Laboratories Stock Up 2.8%

Abbott Laboratories recently traded around $102.56 on October 23, 2026. The stock sits below its 50-day moving average of $105.32 but above its 200-day moving average of $102.33. Shares rest 22.3% below their 52-week high of $132.03 and 25.1% above their 52-week low of $81.97.

Recent Earnings

Abbott Laboratories reported trailing twelve-month revenue of $48.23 billion and earnings of $2.69 per share. The company achieved a year-over-year revenue growth rate of 14.5% and a net profit margin of 9.7%. Return on equity stands at strong levels, and the next earnings report is scheduled for release on January 28, 2027.

Dividend

Abbott Laboratories pays an annual dividend rate of $2.52 per share, which translates to a dividend yield of 2.46%. The company's dividend payout ratio is 78.7%.

Insider Buying and Selling at Abbott Laboratories

Company insiders have completed several stock transactions over recent months. Director John G. Stratton purchased 2,000 shares on May 7, 2026, at an average price of $86.82, totaling $173,640. Officer Louis H. Morrone sold 5,850 shares on August 11, 2026, at $109.83 per share for a total value of $642,506. Chief Executive Officer Robert B. Ford disposed of 398,832 shares on August 25, 2026, valued at $46.20 million, and officer John A. McCoy Jr. sold 27 shares on September 2, 2026, at $109.54 per share worth $2,958.

Analysts Set New Price Targets

Wall Street holds a consensus recommendation key of strong buy for Abbott Laboratories, with a mean price target of $118.60 across 26 analyst opinions. Price targets range from a low of $103.00 to a high of $130.00.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide through four primary business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Headquartered in Abbott Park, Illinois, the company employs approximately 115,000 people and serves patients and medical professionals globally.

Bottom Line

Wells Fargo's updated price target of $120.00 points to modest upside from recent trading levels near $102.56. Investors will look toward the company's next earnings report on January 28, 2027, for further insight into device and pharmaceutical demand.